Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation

Christopher Kanakry • 25 Oct 2019
COSTEM 2019
General Cyclophosphamide

Christopher Kanakry, MD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, talks on the optimal graft versus host disease (GVHD) prophylaxis in T-cell repleted haploidentical transplantation at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Christopher Kanakry

1:51
Insights into the efficacy of different strategies to prevent acute & chronic GvHD
Christopher Kanakry • 28 Oct 2022
6:05
Is it possible to efficiently prevent GvHD with a modified PTCy dosing schedule?
Christopher Kanakry • 28 Oct 2022
4:25
Post-transplant cyclophosphamide mechanisms
Christopher Kanakry • 26 Oct 2019

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals